UK markets closed
  • FTSE 100

    7,500.89
    +34.98 (+0.47%)
     
  • FTSE 250

    20,338.96
    +93.53 (+0.46%)
     
  • AIM

    933.20
    +4.84 (+0.52%)
     
  • GBP/EUR

    1.1820
    +0.0002 (+0.02%)
     
  • GBP/USD

    1.2139
    -0.0064 (-0.52%)
     
  • BTC-GBP

    20,192.48
    -60.61 (-0.30%)
     
  • CMC Crypto 200

    574.64
    +3.36 (+0.59%)
     
  • S&P 500

    4,280.15
    +72.88 (+1.73%)
     
  • DOW

    33,761.05
    +424.38 (+1.27%)
     
  • CRUDE OIL

    91.88
    -2.46 (-2.61%)
     
  • GOLD FUTURES

    1,818.90
    +11.70 (+0.65%)
     
  • NIKKEI 225

    28,546.98
    +727.65 (+2.62%)
     
  • HANG SENG

    20,175.62
    +93.19 (+0.46%)
     
  • DAX

    13,795.85
    +101.34 (+0.74%)
     
  • CAC 40

    6,553.86
    +9.19 (+0.14%)
     

Breaking up is not for us, Bayer CEO says

  • Oops!
    Something went wrong.
    Please try again later.
·1-min read
FILE PHOTO: Logo of Bayer AG is pictured at the annual results news conference of the German drugmaker in Leverkusen
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

BERLIN (Reuters) - German drugs and pesticides maker Bayer has no plans to split its three main businesses into separately traded companies, Chief Executive Werner Baumann said, amid a flurry of conglomerates moving to break themselves up.

"We are going to continue the course, which is developing our company along the three pillars that we have - pharmaceuticals, crop science and consumer health," Baumann told Bloomberg in an interview published on Thursday.

The comments come after conglomerates such as Johnson & Johnson, Toshiba and General Electric announced plans this month to split up, aiming to simplify their structures and increase focus.

Baumann said the decision to continue running the three units under the same roof was made by the company's management and supported by its supervisory board.

"What's right for one company is not necessarily the right thing for the other company," Baumann said, adding all Bayer's three units had life sciences as a platform.

Baumann's comments reiterate what he said in 2018 after analysts called for a break-up to bolster the company's flagging share price.

Some analysts have said Bayer's stock suffers from a conglomerate discount because it combines businesses with few synergies.

In August, Bayer's non-executive board chairman Norbert Winkeljohann also rejected a break-up.

"Dividing up the company would not create value but destroy it. That can't be in the interest of shareholders," Winkeljohann told Manager Magazin.

(Reporting by Riham Alkousaa; Editing by Mark Potter)

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting